Expert Interview
A Second Opinion: Looking at the current use of MRD testing in oncology and Natera's data on their Signatera MRD studies for solid tumors
Ticker(s): NTRA, GH, ADPTInstitution: Terrebonne General Health System
- Medical Director at Terrebonne General | May Bird Perkins Cancer Center
- Orders 5 MRD and 10 NGS tests monthly for oncology patients
- Specializes in various cancers, including breast, lung, GI, lymphoma, and myeloma.
Roughly how many patients do you see per month for blood cancers (Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorder (MPD), Multiple Myeloma)?
Added By: ben_adminHave you ordered any of the following Measurable residual disease (MRD) tests: A) Signatera from Natera Oncology, B) Reveal from Guardant Health, C) ClonoSEQ from Adaptive Biotech?
Added By: ben_adminWhat are the differences between the current MRD tests on the market?
Added By: ben_adminin what indications/ cancer types are you using Signatera the most and has this changed? any growing use cases/indications? What about adoption of signatera throughout your clinic?
Are you familiar with NTRA's Galaxy and ALTAIR trials and if so what are the clinical benchmarks, in your view, that could impact physician adoption? (would overall survival data in the Galaxy readout have an impact on adoption)?
Added By: user5f1fb43bAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
